Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Research Grant to Fund Development of Novel Tumor-Imaging Nanoprobes

By BiotechDaily International staff writers
Posted on 04 Nov 2013
Print article
Research funds have been awarded that will support a collaborative effort to develop novel nanoprobes to be used for in vivo tumor imaging.

Rockland Immunochemicals Inc. (Gilbertsville, PA, USA) and Abzyme Therapeutics (Malvern, PA, USA) have received a Phase I Small Business Innovation Research (SBIR) grant from the [US] National Cancer Institute (Bethesda, MD, USA) to develop nanoprobes for in vivo imaging of tumors that express the important cancer therapeutic targets: EGFR (epidermal growth factor receptor), Her2 (human epidermal growth factor receptor 2), or mesothelin.

According to the terms of the grant, during the first phase the partners will develop, label, and characterize high-affinity single domain antibodies against the three tumor antigens. Abzyme Therapeutics will develop the single domain antibodies, and Rockland will be responsible for bioconjugation and in vivo characterization.

In the planned second phase of the project, the key antibodies will be labeled with a radioactive isotope and characterized using PET scanners in collaboration with Yale University (New Haven, CT, USA) and the University of Pittsburg (PA, USA). Suitable radioactively labeled antibodies will be used as in vivo imaging agents, and their potential use in targeted cancer therapy will be considered.

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop, and commercialize technologies that will ultimately benefit humanity,” said Jim Fendrick, president and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

According to the market research firm Markets and Markets (Pune, India), the global diagnostic imaging market, which stood at USD 20.7 billion in 2010, is expected to expand to USD 26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

Related Links:
Rockland Immunochemicals Inc.
Abzyme Therapeutics
[US] National Cancer Institute




Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.